BBIO
BridgeBio Pharma, Inc. · Healthcare · Market cap $13.2B
Insiders sold $22.3M net in the last 90 days ·5 sellers, 0 buyers· 10 of 10 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 21, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$117.4M
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Sep 21, 2026
Kumar Neil
BridgeBio Pharma, Inc. (BBIO) has 61 SEC Form 4 filings (221 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Sep 21, 2026.
Inside the rolling window, 10 insiders at BridgeBio Pharma, Inc. reported no open-market purchases and 50 open-market sales totaling $117.4M. The most active filer is Chief Executive Officer Kumar Neil with 23 filings. Insiders have net sold $47.7M over the trailing 6 months. The most recent open-market filing is a sale of 10,000 shares by Chief Executive Officer Kumar Neil, dated Sep 17, 2026, worth $691K.
- Industry:Biotechnology
- CEO:Neil Kumar
- Employees:999
- HQ:Palo Alto, CA, US
- IPO:2019-06-27
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 10,000 | $691K | Sep 21 | +1.7% | SEC ↗ | |
| Chief Executive Officer | Sale | 34,980 | $2.9M | Aug 20 | -18.3% | SEC ↗ | |
| Chief Executive Officer | Sale | 10,000 | $840K | Aug 20 | -18.3% | SEC ↗ | |
Apuli MaricelFirst in 3 months | Chief Accounting Officer | Sale | 2,000 | $160K | Aug 3 | -15.3% | SEC ↗ |
Ellis AndreaFirst in 4 months | Director | Sale | 17,167 | $1.4M | Jul 13 | — | SEC ↗ |
| Director | Sale | 148,589 | $13.2M | Jul 13 | — | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | — | SEC ↗ | |
| Director | Sale | 37,167 | $2.6M | Jun 24 | — | SEC ↗ | |
| Director | Sale | 2,808 | $191K | Jun 24 | — | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | — | SEC ↗ | |
Cook Jennifer E.First filing | Director | Sale | 90,240 | $6.0M | Jun 17 | — | SEC ↗ |
| Chief Executive Officer | Sale | 35,921 | $2.4M | Jun 8 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 31,563 | $2.1M | Jun 8 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 26,103 | $1.8M | May 26 | — | SEC ↗ | |
Scott Randal W.First in 3 months | Director | Sale | 10,000 | $671K | May 19 | — | SEC ↗ |
Trimarchi ThomasFirst in 3 months | President and CFO | Sale | 13,651 | $888K | May 19 | — | SEC ↗ |
| Chief Executive Officer | Sale | 40,000 | $2.7M | May 11 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 39,050 | $2.6M | May 11 | — | SEC ↗ | |
| Chief Accounting Officer | Sale | 2,000 | $143K | May 4 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Apr 13 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Apr 13 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 39,700 | $2.7M | Mar 16 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.8M | Mar 16 | — | SEC ↗ | |
| Director | Sale | 8,671 | $624K | Mar 12 | — | SEC ↗ | |
Ellis AndreaFirst filing | Director | Sale | 64,921 | $4.2M | Mar 6 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading BBIO 13 all-time
- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-11
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-05-11
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-04-29
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-04-29
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-03-03
- DRep. Gilbert Ray CisnerosPurchase$1,001 - $15,0002026-03-19
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does BBIO have?
BridgeBio Pharma, Inc. (BBIO) has 61 SEC Form 4 filings (221 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Sep 21, 2026.
When was the most recent SEC Form 4 filing for BBIO?
The most recent Form 4 filing for BBIO on Tracefour is dated Sep 21, 2026.
Who is the most active insider at BBIO?
The most active SEC Form 4 filer at BBIO in the rolling window is Chief Executive Officer Kumar Neil, with 23 filings.
What is the net insider flow at BBIO over the last 6 months?
Over the trailing 180 days, insiders at BBIO have net sold $47.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at BBIO in the current window?
Inside the rolling window, insiders at BBIO bought $0 and sold $117.4M based on SEC Form 4 filings.
Can I get alerts for BBIO insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at BridgeBio Pharma, Inc. (BBIO). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
BridgeBio Pharma, Inc. is in the Healthcare sector.